Department of General Surgery, The Second Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan 646000, P.R. China.
Department of Neonatology, The Second Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan 646000, P.R. China.
Int J Mol Med. 2018 Apr;41(4):2169-2176. doi: 10.3892/ijmm.2018.3396. Epub 2018 Jan 17.
In the present study, an artificial zinc-finger transcription factor eukaryotic expression vector specifically recognizing and binding to the hepatitis B virus (HBV) enhancer (Enh) was constructed, which inhibited the replication and expression of HBV DNA. The HBV EnhI‑specific pcDNA3.1‑artificial transcription factor (ATF) vector was successfully constructed, and then transformed or injected into HepG2.2.15 cells and HBV transgenic mice, respectively. The results demonstrated that the HBV EnhI (1,070‑1,234 bp)‑specific ATF significantly inhibited the replication and transcription of HBV DNA in vivo and in vitro. The HBV EnhI‑specific ATF may be a meritorious component of progressive combination therapies for eliminating HBV DNA in infected patients. A radical cure for chronic HBV infection may become feasible by using this bioengineering technology.
在本研究中,构建了一种人工锌指转录因子真核表达载体,该载体能够特异性识别和结合乙型肝炎病毒(HBV)增强子(Enh),从而抑制 HBV DNA 的复制和表达。成功构建了 HBV EnhI 特异性 pcDNA3.1-人工转录因子(ATF)载体,分别转染或注射入 HepG2.2.15 细胞和 HBV 转基因小鼠。结果表明,HBV EnhI(1,070-1,234 bp)特异性 ATF 可显著抑制 HBV DNA 在体内和体外的复制和转录。HBV EnhI 特异性 ATF 可能是消除感染患者 HBV DNA 的逐步联合治疗方案的有价值组成部分。通过使用这项生物技术,慢性 HBV 感染的根治可能成为可行的。